

REPOS THERAPEUTICS INC.

Form 8-K

September 05, 2006

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**Form 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): 09/05/2006**

**Repos Therapeutics Inc.**

(Exact name of registrant as specified in its charter)

**Commission File Number: 001-15281**

**Delaware**  
(State or other jurisdiction of  
incorporation)

**76-0233274**  
(IRS Employer  
Identification No.)

**2408 Timberloch Place, Suite B-7**  
The Woodlands, Texas 77380  
(Address of principal executive offices, including zip code)

**(281) 719-3400**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

# Edgar Filing: REPOS THERAPEUTICS INC. - Form 8-K

Information to be included in the report

## Item 8.01. Other Events

In a press release on September 5, 2006, Repros Therapeutics Inc. (the "Company") provided an update regarding the progress of its three ongoing clinical studies. The studies include a 200 patient U.S. Phase 3 study of Androxal(TM) for the treatment of testosterone deficiency in men with secondary hypogonadism, a 150 patient U.S. Phase 2 study of Proellex(TM) in the treatment of uterine fibroids and a 40 patient European Phase 2 study of Proellex(TM) in the treatment of endometriosis.

In a press release on September 5, 2006, the Company announced that it has filed a Form S-3 shelf registration statement with the Securities and Exchange Commission for up to 5,000,000 shares of common stock. This shelf registration statement is not yet effective, but if it is declared effective it will remain so for three years. The shares of common stock under this registration statement may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.

A copy of the Company's press releases are attached hereto as Exhibit 99.1 and Exhibit 99.2. The press releases are incorporated by reference herein and the foregoing description of the press releases are qualified in their entirety by reference to the attached exhibits.

## Item 9.01. Financial Statements and Exhibits

c. Exhibits

### Exhibit

Number	Description
99.1	Press Release dated September 5, 2006.
99.2	Press Release dated September 5, 2006.

---

### Signature(s)

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Repos Therapeutics Inc.

Date: September 05, 2006

By: /s/ Louis Ploth, Jr.

---

Louis Ploth, Jr.  
Vice President, Business Development and Chief Financial Officer

**Exhibit Index**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
EX-99.1	Press Release dated September 5, 2006.
EX-99.2	Press Release dated September 5, 2006.